Kamada seeks FDA nod for inhaled CF drug trials

10/21/2007 | Globes (Israel)

Israel-based Kamada Ltd. has submitted an application to the FDA for authorization to conduct midstage studies on an inhaled version of Alpha-1 Antitrypsin, the biopharma company's cystic fibrosis treatment. AAT, which is also being developed for the treatment of other illnesses, such as respiratory diseases, could be a cheaper alternative to intravenous drugs for cystic fibrosis, said Kamada CEO David Tsur.

View Full Article in:

Globes (Israel)

Published in Brief:

SmartBrief Job Listings for Health Care